Chinese Journal of Cancer Research
Overview
Chinese Journal of Cancer Research is a scientific journal, published since 1988 in English. The journal's country of origin is China and its primary focus area is oncology.
Details
Recent Articles
1.
Bi Z, Ren T, Wang Y
Chin J Cancer Res
. 2025 Mar;
37(1):115-117.
PMID: 40078564
The latest data from the NATALEE trial showed the absolute 3-year invasive disease-free survival benefit was 4.9% between the experimental and control groups. That is to say, in the intermediate-risk...
2.
Zhang W, Zhu J, Zhang M, Chang J, Liu J, Chen L, et al.
Chin J Cancer Res
. 2025 Mar;
37(1):1-11.
PMID: 40078563
Objective: Neuroblastoma is the most common extracranial solid tumor in children and has complex genetic underpinnings. Previous genome-wide association studies (GWASs) have identified many loci associated with neuroblastoma susceptibility; however,...
3.
Zhang S, Wang H, Zhang H, Zhuang Q, Zhu X, Xiao Y, et al.
Chin J Cancer Res
. 2025 Mar;
37(1):48-65.
PMID: 40078562
Objective: Recurrence continues to be a pivotal challenge among hormone receptor-positive (HR)/human epidermal growth factor receptor 2-negative (HER2) breast cancers. In the international consensus guidelines, HR/HER2 breast cancer relapse patterns...
4.
Fan B, Su H, Wang L, Ji X, Zhang Y, Jia Z, et al.
Chin J Cancer Res
. 2025 Mar;
37(1):66-72.
PMID: 40078561
Objective: The trial was designed to evaluate the efficacy of prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin for patients with locally advanced gastric cancer (LAGC). Methods: Between March 2015 and...
5.
Ding T, He L, Lin G, Xu L, Zhu Y, Wang X, et al.
Chin J Cancer Res
. 2025 Mar;
37(1):90-114.
PMID: 40078560
Objective: Prostate cancer (PCa) is a complex disease characterized by diverse cellular ecosystems within the tumor microenvironment (TME) and high tumor heterogeneity, which challenges clinically stratified management and reinforces the...
6.
Wang Q, Zhao F, Zhang H, Chu T, Wang Q, Pan X, et al.
Chin J Cancer Res
. 2025 Mar;
37(1):28-47.
PMID: 40078559
Objective: Early predicting response before neoadjuvant chemotherapy (NAC) is crucial for personalized treatment plans for locally advanced breast cancer patients. We aim to develop a multi-task model using multiscale whole...
7.
Yin X, Lu Y, Cui Y, Zhou Z, Wen J, Huang Z, et al.
Chin J Cancer Res
. 2025 Mar;
37(1):12-27.
PMID: 40078558
Objective: The neglect of occult lymph nodes metastasis (OLNM) is one of the pivotal causes of early non-small cell lung cancer (NSCLC) recurrence after local treatments such as stereotactic body...
8.
He T, Zhang J, Zeng L, Yin Z, Yu B, Zhang X, et al.
Chin J Cancer Res
. 2025 Mar;
37(1):73-89.
PMID: 40078557
Objective: The expression of programmed death 1 (PD-1) on CD8 T cells is associated with their activation and exhaustion, while CD57 serves as a senescence marker. The impact of PD-1...
9.
Shi C, Mu Z, Guo W, Zhang X, Sun D, Sun Y, et al.
Chin J Cancer Res
. 2025 Jan;
36(6):700-712.
PMID: 39802903
Objective: This study investigated the clinical significance of mutations in patients with distant metastatic follicular cell-derived thyroid cancer (FDTC). Methods: This study included 310 Chinese patients with distant metastatic FDTC....
10.
Microbiota and urinary tumor immunity: Mechanisms, therapeutic implications, and future perspectives
Li D, Wu R, Yu Q, Tuo Z, Wang J, Yoo K, et al.
Chin J Cancer Res
. 2025 Jan;
36(6):596-615.
PMID: 39802902
No abstract available.